Skip to main content
Top
Published in: Current Urology Reports 3/2010

01-05-2010

Active Surveillance for Prostate Cancer: A Review

Author: Laurence Klotz

Published in: Current Urology Reports | Issue 3/2010

Login to get access

Abstract

Active surveillance is a solution to the widely acknowledged problem of overdiagnosis and overtreatment of clinically insignificant disease which accompanies early detection of prostate cancer using prostate-specific antigen (PSA) and biopsy. It is an approach to the management of favorable-risk prostate cancer which uses the opportunity provided by the long natural history of the disease to incorporate a period of initial observation into patient management. The basic concept is that most men diagnosed with low-grade, small-volume disease are not destined to have any clinical manifestations of the condition during their lifetime. However, a subset of patients with favorable-risk prostate cancer is at risk, due to either the presence of higher-risk disease not apparent at diagnosis or progression to a more aggressive phenotype over time. These patients can be identified with reasonable accuracy by close follow-up, including serial PSAs and biopsies, and treated effectively in most cases. The rationale, patient selection, method of follow-up, triggers for intervention, and recent results of this approach will be reviewed.
Literature
1.
go back to reference Schröder FH, Hugosson J, Roobol MJ, et al.; ERSPC Investigators: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320–1328.CrossRefPubMed Schröder FH, Hugosson J, Roobol MJ, et al.; ERSPC Investigators: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320–1328.CrossRefPubMed
2.
go back to reference Roobol MJ, Kerkhof M, Schröder FH, et al.: Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009, 56:584–591.CrossRefPubMed Roobol MJ, Kerkhof M, Schröder FH, et al.: Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009, 56:584–591.CrossRefPubMed
3.
4.
go back to reference Sakr WA, Haas GP, Cassin BF, et al.: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993, 150:379–385.PubMed Sakr WA, Haas GP, Cassin BF, et al.: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993, 150:379–385.PubMed
5.
go back to reference Welch HG, Albertsen PC: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 2009, 101:1325–1329.CrossRefPubMed Welch HG, Albertsen PC: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 2009, 101:1325–1329.CrossRefPubMed
6.
go back to reference Presti JC Jr: Prostate biopsy: how many cores are enough? Urol Oncol 2003, 21:135–140.PubMed Presti JC Jr: Prostate biopsy: how many cores are enough? Urol Oncol 2003, 21:135–140.PubMed
7.
go back to reference D’Amico AV, Whittington R, Malkowicz SB, et al.: Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002, 95:281–286.CrossRefPubMed D’Amico AV, Whittington R, Malkowicz SB, et al.: Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002, 95:281–286.CrossRefPubMed
8.
go back to reference Cooperberg MR, Broering JM, Kantoff PW, Carroll PR: Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007, 178:S14–S19.CrossRefPubMed Cooperberg MR, Broering JM, Kantoff PW, Carroll PR: Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007, 178:S14–S19.CrossRefPubMed
9.
go back to reference Albertsen PC, Hanley JA, Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095–2101.CrossRefPubMed Albertsen PC, Hanley JA, Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095–2101.CrossRefPubMed
10.
go back to reference Albertsen PC, Hanley JA, Barrows GH, et al.: Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005, 97:1248–1253.PubMedCrossRef Albertsen PC, Hanley JA, Barrows GH, et al.: Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005, 97:1248–1253.PubMedCrossRef
11.
go back to reference Draisma G, Boer R, Otto SJ, et al.: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003, 95:868–878.PubMed Draisma G, Boer R, Otto SJ, et al.: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003, 95:868–878.PubMed
12.
go back to reference Törnblom M, Eriksson H, Franzén S, et al.: Lead time associated with screening for prostate cancer. Int J Cancer 2004, 108:122–129.CrossRefPubMed Törnblom M, Eriksson H, Franzén S, et al.: Lead time associated with screening for prostate cancer. Int J Cancer 2004, 108:122–129.CrossRefPubMed
13.
go back to reference Bill-Axelson A, Holmberg L, Ruutu M, et al.; Scandinavian Prostate Cancer Group Study No. 4: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005, 352:1977–1984.CrossRefPubMed Bill-Axelson A, Holmberg L, Ruutu M, et al.; Scandinavian Prostate Cancer Group Study No. 4: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005, 352:1977–1984.CrossRefPubMed
14.
go back to reference Choo R, Klotz L, Danjoux C, et al.: Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002, 167:1664–1669.CrossRefPubMed Choo R, Klotz L, Danjoux C, et al.: Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002, 167:1664–1669.CrossRefPubMed
15.
go back to reference Klotz L, Zhang L, Lam A, et al.: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010, 28:126–131.CrossRefPubMed Klotz L, Zhang L, Lam A, et al.: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010, 28:126–131.CrossRefPubMed
16.
go back to reference Khatami A, Aus G, Damber JE, et al.: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007, 120:170–174.CrossRefPubMed Khatami A, Aus G, Damber JE, et al.: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007, 120:170–174.CrossRefPubMed
17.
go back to reference Soloway MS, Soloway CT, Williams S, et al.: Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 2008, 101:165–169.PubMed Soloway MS, Soloway CT, Williams S, et al.: Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 2008, 101:165–169.PubMed
18.
go back to reference Carter HB, Kettermann A, Warlick C, et al.: Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007, 178:2359–2364.CrossRefPubMed Carter HB, Kettermann A, Warlick C, et al.: Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007, 178:2359–2364.CrossRefPubMed
19.
go back to reference Parker C: Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004, 5:101–106.CrossRefPubMed Parker C: Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004, 5:101–106.CrossRefPubMed
20.
go back to reference van As NJ, Parker CC: Active surveillance with selective radical treatment for localized prostate cancer. Cancer J 2007, 13:289–294.CrossRefPubMed van As NJ, Parker CC: Active surveillance with selective radical treatment for localized prostate cancer. Cancer J 2007, 13:289–294.CrossRefPubMed
21.
go back to reference Roemeling S, Roobol MJ, de Vries SH, et al.: Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 2007, 51:1244–1250.CrossRefPubMed Roemeling S, Roobol MJ, de Vries SH, et al.: Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 2007, 51:1244–1250.CrossRefPubMed
22.
go back to reference van den Bergh RC, Roemeling S, Roobol MJ, et al.: Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009, 55:1–8.CrossRefPubMed van den Bergh RC, Roemeling S, Roobol MJ, et al.: Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009, 55:1–8.CrossRefPubMed
23.
go back to reference van den Bergh RC, Vasarainen H, van der Poel HG, et al.: Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study. BJU Int 2009 Oct 8 (Epub ahead of print). van den Bergh RC, Vasarainen H, van der Poel HG, et al.: Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study. BJU Int 2009 Oct 8 (Epub ahead of print).
24.
go back to reference Shappley WV 3rd, Kenfield SA, Kasperzyk JL, et al.: Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009, 27:4980–4985.CrossRefPubMed Shappley WV 3rd, Kenfield SA, Kasperzyk JL, et al.: Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009, 27:4980–4985.CrossRefPubMed
25.
go back to reference Zhang L, Loblaw A, Klotz L: Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol 2006, 176:1392–1397.CrossRefPubMed Zhang L, Loblaw A, Klotz L: Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol 2006, 176:1392–1397.CrossRefPubMed
26.
go back to reference D’Amico AV, Chen MH, Roehl KA, Catalona WJ: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004, 351:125–135.CrossRefPubMed D’Amico AV, Chen MH, Roehl KA, Catalona WJ: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004, 351:125–135.CrossRefPubMed
27.
go back to reference Scattoni V, Zlotta A, Montironi R, et al.: Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007, 52:1309–1322.CrossRefPubMed Scattoni V, Zlotta A, Montironi R, et al.: Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007, 52:1309–1322.CrossRefPubMed
28.
go back to reference Lawrentschuk N, Haider MA, Daljeet N, et al.: ‘Prostatic evasive anterior tumours’: the role of magnetic resonance imaging. BJU Int 2009 Oct 8 (Epub ahead of print). Lawrentschuk N, Haider MA, Daljeet N, et al.: ‘Prostatic evasive anterior tumours’: the role of magnetic resonance imaging. BJU Int 2009 Oct 8 (Epub ahead of print).
29.
go back to reference Steineck G, Helgesen F, Adolfsson J, et al.; Scandinavian Prostatic Cancer Study Group Number 4: Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002, 347:790–796.CrossRefPubMed Steineck G, Helgesen F, Adolfsson J, et al.; Scandinavian Prostatic Cancer Study Group Number 4: Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002, 347:790–796.CrossRefPubMed
30.
go back to reference Burnet KL, Parker C, Dearnaley D, et al.: Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int 2007, 100:540–543.CrossRefPubMed Burnet KL, Parker C, Dearnaley D, et al.: Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int 2007, 100:540–543.CrossRefPubMed
31.
go back to reference Graif T, Loeb S, Roehl KA, et al.: Under diagnosis and over diagnosis of prostate cancer. J Urol 2007, 178:88–92.CrossRefPubMed Graif T, Loeb S, Roehl KA, et al.: Under diagnosis and over diagnosis of prostate cancer. J Urol 2007, 178:88–92.CrossRefPubMed
32.
go back to reference Hou AH, Sullivan KF, Crawford ED: Targeted focal therapy for prostate cancer: a review. Curr Opin Urol 2009, 19:283–289.CrossRefPubMed Hou AH, Sullivan KF, Crawford ED: Targeted focal therapy for prostate cancer: a review. Curr Opin Urol 2009, 19:283–289.CrossRefPubMed
33.
go back to reference Zheng SL, Sun J, Wiklund F, et al.: Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008, 358:910–919.CrossRefPubMed Zheng SL, Sun J, Wiklund F, et al.: Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008, 358:910–919.CrossRefPubMed
34.
go back to reference Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215–224.CrossRefPubMed Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215–224.CrossRefPubMed
35.
go back to reference Andriole G, Bostwick D, Brawley O, et al.: Further analyses from the REDUCE prostate cancer risk reduction trial [abstract LBA1]. Presented at the 2009 American Urological Association Annual Meeting (Late Breaking Science Forum). Chicago, Illinois; April 25–30, 2009. Andriole G, Bostwick D, Brawley O, et al.: Further analyses from the REDUCE prostate cancer risk reduction trial [abstract LBA1]. Presented at the 2009 American Urological Association Annual Meeting (Late Breaking Science Forum). Chicago, Illinois; April 25–30, 2009.
Metadata
Title
Active Surveillance for Prostate Cancer: A Review
Author
Laurence Klotz
Publication date
01-05-2010
Publisher
Current Science Inc.
Published in
Current Urology Reports / Issue 3/2010
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-010-0110-z

Other articles of this Issue 3/2010

Current Urology Reports 3/2010 Go to the issue